Kilitch Drugs (India) Limited
Valuation (99/100) does the heavy lifting; quality (65/100) is the drag.
Buy zoneOur blended model reads Kilitch Drugs (India) Limited as a Strong Buy at 83/100. At ₹186.59 it trades below our blended DCF and relative-multiples fair value of ₹324.44, about 74% upside to that estimate — we read it as undervalued by 74%. On 21.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 17% below its 52-week high of ₹224.4 and 50% above the low of ₹124.45. Financial health scores 65/100, with a Piotroski F-score of 1/9. It clears 9 of 12 investability checks, with durability 65, valuation 97 and momentum 81 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹259.55.
1-year price
EOD · 2026-07-3152-week range
-16.85% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy83Piotroski F-score 1/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 12.4%
- Pass: Low debt (D/E < 0.5): 0.32x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 46%
- Pass: Earnings growing: 27%
- Pass: Net margin ≥ 10%: 12.8%
- Pass: Current ratio > 1.5: 1.83
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- No data: Altman Z in safe zone
- Fail: Piotroski ≥ 7: 1/9
Shareholding
- Promoter72.2%
- Institutions0.0%
- Public & other27.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
Opportunities
- Earnings growing (27% YoY).
- Revenue growing (46% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~74% below our estimated fair value.
Bear case
Weaknesses
- Weak Piotroski score (1/9).
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited develops and operates a pharmaceutical business in India and internationally. The company manufactures parenteral, nasal, and topical products, including liquid ampoules, vials, dry powder injectables, and metered nasal drops for therapeutic areas including gastroenterology, anti-inflammatory, anticonvulsant, anti-malarial, antibacterial, anti-hypertensive, and anti-infective applications.
Kilitch Drugs (India) Limited — frequently asked questions
Is Kilitch Drugs (India) Limited a buy, hold or sell?
StocksWizard currently rates Kilitch Drugs (India) Limited (KILITCH) a Strong Buy, based on a blended score of 83/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Kilitch Drugs (India) Limited's fair value?
Our blended DCF and relative-valuation model estimates Kilitch Drugs (India) Limited's fair value at about ₹324.44, versus a current price of ₹186.59 — roughly 74% upside. On that basis the stock looks undervalued by 74%.
Is Kilitch Drugs (India) Limited financially healthy?
Kilitch Drugs (India) Limited scores 65/100 on our financial-health model, with a Piotroski F-score of 1/9.
How has Kilitch Drugs (India) Limited's share price performed?
Kilitch Drugs (India) Limited is up 22% over three months, and last traded at ₹186.59. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.